PARIS – French pharmaceutical giant Sanofi announced that it would manufacture 125 million doses of the vaccine for the coronavirus developed by rivals Pfizer and BioNTech, ahead of the launch of its candidate.
The German BioNTech will initially produce the vehicles in Sanofi’s installations in Frankfurt as part of the move, exploring Sanofi in a communication. The company did not reveal the financial details of the agreement.
The governor of France has been pressuring Sanofi to employ its facilities to help manufacture the vacancies of its competitors by requesting the elevation and the problems with the vacancy summit available.
“We are very aware of the extent to which vacancies are available as soon as possible, more than ever before,” Sanofi CEO Paul Hudson said in a statement.
Sanofi and its British company GlaxoSmithKline are launching a new Phase 2 drive for their Covid-19 vehicle next month, the company added. The two pharmaceutical companies announced last month that their pharmacy will not be on the final list of 2021 because they must increase their efficacy between the mayors.
The European Union has received generalized criticism for the slow pace of a massive evacuation program. The block approves the use of the vacancies of Pfizer-BioNTech and Modern, and the European Medicines Agency will study the four cities that are being developed by AstraZeneca and the University of Oxford.